Xin-Min Wang
United States Military Academy
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xin-Min Wang.
Journal of Immunological Methods | 2001
Timothy W Tobery; Su Wang; Xin-Min Wang; Michael P. Neeper; Kathrin U. Jansen; William L. Mcclements; Michael J. Caulfield
In this study, we describe a simple and efficient method for both the monitoring of antigen-specific CD4 and CD8 T cell responses as well as the identification of novel CD4 and CD8 T cell epitopes using a modified ELISpot assay and pools of 20mer peptides. We have demonstrated that pools containing as many as 64 20mer peptides may be used to screen for CD4 and CD8 T cell responses to HPV16 L1, E1, and E7 in mice. Using arrays of pools of overlapping 20mer peptides, we have identified novel CD4 and CD8 epitopes in both HPV16L1 and HPV16E1 which are presented in Balb/c mice. We have further shown that the use of 20mer peptides is equivalent to using minimal 9mer epitopes for the stimulation of CD8 T cell responses in our assay. While our experiments are conducted in mice, the use of peptide pool arrays allows for the identification of epitope-specific responses using far fewer cells than is required for testing a panel of overlapping peptides individually, making this strategy particularly useful in clinical settings where immune cells may be limiting.
Clinical and Vaccine Immunology | 2009
Martha Brown; Rose Kowalski; Julie Zorman; Xin-Min Wang; Victoria Towne; Qinjian Zhao; Susan Secore; Adam C. Finnefrock; Tim Ebert; Greg Pancari; Kevin Isett; Yuhua Zhang; Annaliesa S. Anderson; Donna L. Montgomery; Leslie D. Cope; Tessie McNeely
ABSTRACT In an effort to characterize important epitopes of Staphylococcus aureus iron-regulated surface determinant B (IsdB), murine IsdB-specific monoclonal antibodies (MAbs) were isolated and characterized. A panel of 12 MAbs was isolated. All 12 MAbs recognized IsdB in enzyme-linked immunosorbent assays and Western blots; 10 recognized native IsdB expressed by S. aureus. The antigen epitope binding of eight of the MAbs was examined further. Three methods were used to assess binding diversity: MAb binding to IsdB muteins, pairwise binding to recombinant IsdB, and pairwise binding to IsdB-expressing bacteria. Data from these analyses indicated that MAbs could be grouped based on distinct or nonoverlapping epitope recognition. Also, MAb binding to recombinant IsdB required a significant portion of intact antigen, implying conformational epitope recognition. Four MAbs with nonoverlapping epitopes were evaluated for in vitro opsonophagocytic killing (OPK) activity and efficacy in murine challenge models. These were isotype switched from immunoglobulin G1 (IgG1) to IgG2b to potentially enhance activity; however, this isotype switch did not appear to enhance functional activity. MAb 2H2 exhibited OPK activity (≥50% killing in the in vitro OPK assay) and was protective in two lethal challenge models and a sublethal indwelling catheter model. MAb 13C7 did not exhibit OPK (<50% killing in the in vitro assay) and was protective in one lethal challenge model. Neither MAb 13G11 nor MAb 1G3 exhibited OPK activity in vitro or was active in a lethal challenge model. The data suggest that several nonoverlapping epitopes are recognized by the IsdB-specific MAbs, but not all of these epitopes induce protective antibodies.
Human Vaccines | 2009
James M. Cook; Robert W. Hepler; Greg Pancari; Nelly Kuklin; Hongxia Fan; Xin-Min Wang; Leslie D. Cope; Charles Tan; Joseph G. Joyce; Jan Onishi; Donna L. Montgomery; Annaliesa S. Anderson; Tessie McNeely
Staphylococcus aureus is a clinically important capsule-forming bacterium. The capsule polysaccharide (CPs) occurs as different chemical structures depending on the serotype of the organism, but one form, capsular polysaccharide type 8 (CPs8) found in clinical isolates, is largely unstudied. The potential of CPs8 as a vaccine target was evaluated using two approaches. The first approach used a conjugate vaccine, made by chemically linking purified CPs8 to the outer membrane protein complex of N. meningitidis serotype B (OMPC). In efficacy studies, the CPs8-OMPC conjugate vaccine was immunogenic in Balb/c mice, however the immune response gave no protection from death after a lethal intravenous (iv) challenge with S. aureus Becker. In the second approach, two monoclonal antibodies were produced against CPs8 (MAbs 8E8 and 1C10). These were found to have functional activity in an opsonophagocytic killing assay (OPA), and provided protection from a lethal challenge when bacteria were pre-opsonized ex vivo before intra-peritoneal (ip) challenge. However, MAb 8E8 was not efficacious in the lethal challenge model, in which antibodies were passively transferred to the peritoneum and the animals were infected via the tail vein 18-24 h later. Additionally, the monoclonal antibodies did not opsonize capsule-expressing S. aureus Becker obtained from in vivo growth conditions. These results indicated that functional capsule antibodies may not be sufficient for protection from S. aureus under all in vivo conditions.
Journal of Virological Methods | 2003
Xin-Min Wang; Kathrin U. Jansen; William L. Mcclements
Human papillomavirus (HPV) DNA replication requires functional HPV early (E) proteins E1 and E2. To determine the biological activity of HPV 16 E1 and E2 mutant proteins under consideration as vaccine candidates, we developed a sensitive real time PCR assay that monitors HPV origin-of-replication-driven DNA synthesis. The assay was used to determine the DNA replicative functions of highly-expressed, codon-optimized HPV 16 E1 and E2 wild type and mutant proteins in transient transfections. Under the assay conditions, the HPV 16 E1 mutant (W439R, G482D) did not support HPV origin-driven DNA synthesis. In contrast, however, an HPV 16 E2 mutant bearing an E39A substitution, reported previously to be severely compromised for DNA replication, was found to be reduced only two-fold in activity and, therefore, considered not sufficiently inactivated for use in vaccines that depend on endogenous protein expression.
Virology | 2000
Steven W. Ludmerer; William L. Mcclements; Xin-Min Wang; Jessica C. Ling; Kathrin U. Jansen; Neil D. Christensen
Virology | 2001
William L. Mcclements; Xin-Min Wang; Jessica C. Ling; Dee Marie Skulsky; Neil D. Christensen; Kathrin U. Jansen; Steven W. Ludmerer
Journal of General Virology | 2003
Xin-Min Wang; James C. Cook; Jessica C. Lee; Kathrin U. Jansen; Neil D. Christensen; Steven W. Ludmerer; William L. Mcclements
Archive | 2002
Lingyi Huang; Kathrin U. Jansen; Clements William L. Mc; Juanita Monteiro; Loren D. Schultz; Timothy W Tobery; Xin-Min Wang; Ling Chen
Archive | 1999
Kathrin U. Jansen; Jessica C. Ling; Steven W. Ludmerer; William L. Mcclements; Xin-Min Wang
Archive | 2010
Tim Ebert; Sharon Smith; Greg Pancari; Desmond J. Clark; Richard Hampton; Susan Secore; Victoria Towne; Hongxia Fan; Xin-Min Wang; Xiaoqing Wu; Robin Ernst; Barrett R. Harvey; Adam C. Finnefrock; Fubao Wang; Charles Tan; Eberhard Durr; Leslie D. Cope; Annaliesa S. Anderson; Zhiqiang An; Tessie McNeely